Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: Results of a phase II trial

Chih Yuan Chung, Sheng Fung Lin, Po Min Chen, Ming Chih Chang, Woei You Kao, Tsu Yi Chao, Liang Tsai Hsiao, Chuen Chuan Yen, Muh Hwa Yang, Wei Shou Hwang, Tung Liang Lin, Tzeon Jye Chiou, Cheng Shyong Chang

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Background: Thalidomide inhibits angiogenesis and exerts complex immunomodulatory activities. This phase II study aimed to examine the efficacy of thalidomide in Taiwanese patients with myelodysplastic syndrome (MDS). Patients and Methods: Sixty patients [intention to treat group (ITT)] with MDS were treated with thalidomide (100 mg/day, increased by 100 mg/day weekly to a maximum of 400 mg/day) for 12 weeks. Forty-two patients of the ITT group were considered as comprising the evaluable population (EP). Results: Thalidomide resulted in hematological improvement (HI) in 28% of ITT analysis and in HI in 40% of the EP. Thalidomide was more effective for MDS patients with low to intermediate-1 International Prognostic Score System scores. The response rates were 7% for ITT and 10% for EP patients. Only two patients exhibited a cytogenetic response. Net reduced levels of vascular endothelial growth factor and basic fibroblast growth factor cytokines were observed in the peripheral blood and the bone marrow of thalidomide-treated patients. Conclusion: Low-dose thalidomide is an effective and safe treatment for patients with low-risk MDS.

Original languageEnglish
Pages (from-to)3415-3419
Number of pages5
JournalAnticancer Research
Issue number8
Publication statusPublished - Aug 2012


  • Angiogenesis
  • Hematological improvement
  • Myelodysplastic syndromes
  • Thalidomide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: Results of a phase II trial'. Together they form a unique fingerprint.

Cite this